Biogen (BIIB) Total Debt Growth (5y) (2014 - 2024)
Biogen (BIIB) Total Debt Growth (5y) (2014 - 2024) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
| 1 |
Gsk |
92,316,836.42 Bn |
92,316,831.46 Bn |
7.76 Bn |
| 2 |
Eli Lilly |
983.57 Bn |
978.29 Bn |
16.22 Bn |
| 3 |
Johnson & Johnson |
553.56 Bn |
531.50 Bn |
15.96 Bn |
| 4 |
AbbVie |
383.35 Bn |
374.00 Bn |
10.78 Bn |
| 5 |
Merck |
281.71 Bn |
276.06 Bn |
12.09 Bn |
| 6 |
Amgen |
182.20 Bn |
170.16 Bn |
5.87 Bn |
| 7 |
Gilead Sciences |
153.71 Bn |
145.98 Bn |
5.52 Bn |
| 8 |
Pfizer |
143.75 Bn |
130.98 Bn |
-1.21 Bn |
| 9 |
Bristol Myers Squibb |
109.71 Bn |
99.25 Bn |
8.07 Bn |
| 10 |
Biogen |
28.97 Bn |
24.68 Bn |
1.82 Bn |
| Date | Value |
|---|
| Dec 31, 2024 |
33.30% |
| Dec 31, 2022 |
355.59% |
| Dec 31, 2021 |
192.08% |
| Dec 31, 2019 |
244.11% |
| Mar 31, 2018 |
-65.86% |
| Dec 31, 2017 |
-69.13% |
| Sep 30, 2017 |
-2.73% |
| Jun 30, 2017 |
-2.69% |
| Mar 31, 2017 |
-2.15% |
| Dec 31, 2016 |
-66.17% |
| Sep 30, 2016 |
-65.89% |
| Jun 30, 2016 |
-66.04% |
| Mar 31, 2016 |
-65.92% |
| Dec 31, 2015 |
-66.14% |
| Sep 30, 2015 |
-65.57% |
| Jun 30, 2015 |
-68.61% |
| Mar 31, 2015 |
-68.66% |
| Dec 31, 2014 |
-68.99% |
| Sep 30, 2014 |
-68.78% |
| Jun 30, 2014 |
-68.46% |
